Tag: healthcare

The ACA and Healthcare Industry M&A: What You Need to Know

The Affordable Care Act still is impacting the healthcare industry, affecting players of all sizes from doctors’ offices, hospitals and medical device companies to large pharmaceuticals. Mergers and acquisitions in the healthcare sector have doubled over the same period in 2014. According to Reuters data through April 24, a wave of mergers produced $193.9 billion …

Continue reading

Valeant Acquires Salix in the Latest Wave of Pharmaceutical M&A

Yesterday, Salix Pharmaecuticals accepted Valeant’s raised takeover offer of $10.96 billion in cash, ending the bidding war between Endo and Valeant for the gastrointestinal drug maker. Valeant’s new offer of $173 per share is about a 10% increase over its original offer of $158 per share. Valeant also paid $296 million for assets of bankrupt …

Continue reading

Why Shire Will Pay a Premium for NPS Pharmaceuticals

Shire is buying NPS Pharmaceuticals for $5.2 billion in the first major deal of 2015. You may recall Shire received a lot of press last year for its planned inversion with AbbVie. U.S.-based Abbvie planned to acquire Shire primarily for tax reasons, however the deal fell apart and as a result Shire received a breakup …

Continue reading

Healthcare Services M&A Extraordinarily Strong

Mergers and acquisitions for healthcare services were “extraordinarily strong” in the second quarter of 2014, according to analysis conducted by Scott-Macon. The Affordable Care Act has changed the healthcare industry dramatically, spurring re-alignments across multiple sectors. A wide range of businesses conducted acquisitions in 2Q 2014, including hospitals, private equity, software solution providers and consulting …

Continue reading

Valeant Seeks More Acquisitions

Valeant Pharmaceuticals International is determined to grow through acquisitions.  Already actively pursuing a deal with Allergan, the maker of Botox, Valeant is reportedly seeking another contact lens company. CEO Michael Pearson said the company “will not be content to remain the No. 4 global player in the contact lens industry.” Valeant has a history of …

Continue reading

The Strategy Behind the AbbVie-Shire Acquisition

Here’s a quick thought about the Abbvie – Shire transaction that’s received so much recent attention because of the decision to reincorporate in Ireland once the deal is completed. Tax inversions are in vogue and a hot topic in the media. While the tax benefits of an inversion certainly are important in this acquisition, that’s …

Continue reading

Pharmaceuticals Refocus and Consolidate

Pharmaceutical companies are using acquisition to become “pointy,” or more focused. Two recent examples are Bayer and Merck.  Bayer is focusing on over the counter medications by acquiring Merck’s consumer care business for $14.2 billion. On the other hand, Merck has become more streamlined through divestment. As I’ve mentioned before, although divestment means becoming smaller, …

Continue reading

Why Pfizer Really Wants to Acquire AstraZeneca

Pfizer looks to AstraZeneca acquisition to bolster its drug pipeline and reap tax savings. Pfizer’s $119 billion bid for AstraZenca indicates a change in strategy for the company. According to the Wall Street Journal  “A big deal, potentially worth $100 billion, would mean Pfizer is shifting from its steady diet of cost-cutting and reorganizations over …

Continue reading

New Healthcare Trend: Private Health Exchanges

Healthcare is a hot industry for both PE and strategic buyers as they navigate new regulatory issues posed by the Affordable Care Act. According to Reuters, healthcare was the second largest industry in the U.S. by deal value for the third quarter of 2013. The New York Times reports the number of private exchanges has …

Continue reading

Healthcare M&A Can Only Grow

Two major hospital acquisitions announced this summer will result in huge hospital networks and likely create pressure for other hospital deals.  Tenet will buy Vanguard Health for $1.73 billion and Community Health will buy HMA for $3.6 billion. Combined with Vanguard Health, Tenet will become No. 1 or 2 in 19 key markets, including San …

Continue reading

Load more